Vanda Pharmaceuticals
VNDA
116 hedge funds and large institutions have $345M invested in Vanda Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 38 reducing their positions, and 18 closing their positions.
17% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $1.48M
1% less funds holding
Funds holding: 117 → 116 (-1)
3% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 38
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
13% less capital invested
Capital invested by funds: $396M → $345M (-$51.3M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.18M |
| 3 |
Goldman Sachs
New York
|
+$2.08M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.23M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.2M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$3.86M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$3.33M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$2.94M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$2.48M |
VNDA Hedge Fund Activity: Q1 2016 in Review
116 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2016, worth a combined $345M — down 13% from $396M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VNDA and 17 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 37 added.
The largest buyer was Millennium Management, adding an estimated $5.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.2M sold.
- 116 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2016, down from 117 in Q4 2015.
- Funds reported $345M of Vanda Pharmaceuticals stock for Q1 2016, down 13% quarter-over-quarter.
- 17 funds opened new Vanda Pharmaceuticals positions in Q1 2016 and 18 closed out, a net change of -1 holder.
- The largest Vanda Pharmaceuticals buyer in Q1 2016 was Millennium Management, an estimated $5.2M added.
- The largest Vanda Pharmaceuticals seller in Q1 2016 was Consonance Capital Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2016.